Human Genome Sciences reported that the final results of two pivotal Phase 3 trials demonstrated that Albuferon (albinterferon alfa-2b) met its primary endpoint of non-inferiority to Pegasys (peginterferon alfa-2a) in the treatment of patients with chronic hepatitis C (HCV). The studies known as ACHIEVE 1 and ACHIEVE 2/3, evaluated albinterferon alfa-2b vs. peginterferon alfa-2a, in combination with ribavirin in 2255 interferon-naïve patients. ACHIEVE 1 was conducted in patients infected with genotype 1 virus and ACHIEVE 2/3 was conducted in patients with genotypes 2 and 3 virus.
Albinterferon alfa-2b is a genetic fusion of human albumin and interferon alfa created using the proprietary Human Genome Sciences albumin-fusion technology.
For more information call (301) 309-8504 or visit www.hgsi.com.